Research and Markets: High Level of Competition between Emerging and Currently Marketed Therapeutics

Research and Markets (http://www.researchandmarkets.com/research/7v2rdt/frontier_pharma) has announced the addition of the "Frontier Pharma: Rheumatoid Arthritis - Identifying and Commercializing First-in-Class Innovation" report to their offering.

The RA market contains several of the most profitable therapies across the entire drug industry. Humira (adalimumab), Rituxan (rituximab) Remicade (infliximab) and Enbrel (etanacept) globally generated revenues of $9.3 billion, $7.2 billion, $6.1 billion, $4.2 billion, respectively in 2012, which secured their positions in the top 20 bestselling drugs of that year. In addition, other commercially strong drugs include Actemra (tocilizumab), Simponi (golimumab) and Cimzia (certolizumab), which have individually generated revenues of $600-900m each. All these therapeutics are not very strongly differentiated in terms of clinical efficacy and safety profiles, and all require administration through injection.

Therapeutics entering the market must therefore compete and outperform these dominant drugs in order to sustain a share of the market value. The pipeline for RA is large, with a total of 577 programs, and a high level of first-in-class programs. However, late-stage first-in-class drugs identified as potential market entrants do not appear to offer significant improvements in comparison to the range of targeted therapies already marketed. It appears that the established products will remain as the cornerstone of RA treatment for the time being.

Highly Diversified Range of Innovative Programs in Early Pipeline

Early-stage, first-in-class programs exhibit a high level of diversity with respect to novel therapeutic targets and are not limited to kinase inhibitors and cytokine modulators. Innovative programs also target molecules that have only recently gained acknowledgement of their therapeutic value in the treatment of RA. However, these programs have only been validated in animal models and therefore require further clinical assessment in order to establish how they compete against established antibody therapies.

Key Topics Covered:

1.1 List of Tables

1.2 List of Figures

2 Introduction

3 Clinical and Commercial Landscape

4 Assessment of Pipeline Product Innovation

5 First-in-Class Target and Pipeline Program Evaluation

6 Deals and Strategic Consolidations

7 Appendix

For more information visit http://www.researchandmarkets.com/research/7v2rdt/frontier_pharma.

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager
[e-mail]
U.S. Fax: [phone]
Fax (outside U.S.): [phone]
Sector: Healthcare and Medical Devices, Pharmaceuticals